Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
GSK PHARMA TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
GSK PHARMA Mar-23 |
TEVA PHARMA Dec-13 |
GSK PHARMA/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,684 | 3,479 | - | |
Low | Rs | 1,231 | 3,022 | - | |
Sales per share (Unadj.) | Rs | 191.9 | 1,996.4 | - | |
Earnings per share (Unadj.) | Rs | 35.9 | 124.7 | - | |
Cash flow per share (Unadj.) | Rs | 39.8 | 286.1 | - | |
Dividends per share (Unadj.) | Rs | 32.00 | 109.18 | - | |
Avg Dividend yield | % | 2.2 | 3.4 | 65.4% | |
Book value per share (Unadj.) | Rs | 102.9 | 2,217.6 | - | |
Shares outstanding (eoy) | m | 169.41 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 7.6 | 1.6 | 466.3% | |
Avg P/E ratio | x | 40.6 | 26.1 | 155.9% | |
P/CF ratio (eoy) | x | 36.7 | 11.4 | 322.7% | |
Price / Book Value ratio | x | 14.2 | 1.5 | 966.4% | |
Dividend payout | % | 89.2 | 87.5 | 101.9% | |
Avg Mkt Cap | Rs m | 246,858 | 2,756,220 | 9.0% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 5,950 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,667.6 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,353.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 32,517 | 1,692,969 | 1.9% | |
Other income | Rs m | 1,007 | 0 | - | |
Total revenues | Rs m | 33,524 | 1,692,969 | 2.0% | |
Gross profit | Rs m | 8,033 | 463,620 | 1.7% | |
Depreciation | Rs m | 658 | 136,844 | 0.5% | |
Interest | Rs m | 18 | 33,253 | 0.1% | |
Profit before tax | Rs m | 8,364 | 293,523 | 2.8% | |
Minority Interest | Rs m | 0 | 1,333 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -192,682 | -0.0% | |
Tax | Rs m | 2,288 | -3,584 | -63.8% | |
Profit after tax | Rs m | 6,076 | 105,758 | 5.7% | |
Gross profit margin | % | 24.7 | 27.4 | 90.2% | |
Effective tax rate | % | 27.4 | -1.2 | -2,240.2% | |
Net profit margin | % | 18.7 | 6.2 | 299.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 24,943 | 1,143,425 | 2.2% | |
Current liabilities | Rs m | 13,264 | 997,163 | 1.3% | |
Net working cap to sales | % | 35.9 | 8.6 | 415.7% | |
Current ratio | x | 1.9 | 1.1 | 164.0% | |
Inventory Days | Days | 97 | 91 | 107.2% | |
Debtors Days | Days | 216 | 96 | 225.1% | |
Net fixed assets | Rs m | 6,988 | 552,961 | 1.3% | |
Share capital | Rs m | 1,694 | 4,167 | 40.7% | |
Net worth | Rs m | 17,430 | 1,880,567 | 0.9% | |
Long term debt | Rs m | 0 | 865,653 | 0.0% | |
Total assets | Rs m | 31,930 | 3,868,976 | 0.8% | |
Interest coverage | x | 462.6 | 9.8 | 4,707.3% | |
Debt to equity ratio | x | 0 | 0.5 | 0.0% | |
Sales to assets ratio | x | 1.0 | 0.4 | 232.7% | |
Return on assets | % | 19.1 | 3.6 | 531.2% | |
Return on equity | % | 34.9 | 5.6 | 619.9% | |
Return on capital | % | 48.1 | 4.9 | 975.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 4,842 | 269,772 | 1.8% | |
From Investments | Rs m | 8,079 | -95,591 | -8.5% | |
From Financial Activity | Rs m | -15,433 | -323,609 | 4.8% | |
Net Cashflow | Rs m | -2,512 | -149,429 | 1.7% |
Compare GSK PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare GSK PHARMA With: WANBURY LACTOSE INDIA FREDUN PHARMA NORRIS MEDICINES SANDU PHARMA
Indian share markets continued the momentum as the session progressed and ended the higher.